Novel Pharmaceuticals in Appetite Regulation: Exploring emerging gut peptides and their pharmacological prospects.
amylin
anti‐obesity pharmaceuticals
cholecystokinin
ghrelin
gut peptides
peptide YY
Journal
Pharmacology research & perspectives
ISSN: 2052-1707
Titre abrégé: Pharmacol Res Perspect
Pays: United States
ID NLM: 101626369
Informations de publication
Date de publication:
Aug 2024
Aug 2024
Historique:
revised:
23
03
2024
received:
12
12
2023
accepted:
22
06
2024
medline:
17
7
2024
pubmed:
17
7
2024
entrez:
17
7
2024
Statut:
ppublish
Résumé
Obesity, a global health challenge, necessitates innovative approaches for effective management. Targeting gut peptides in the development of anti-obesity pharmaceuticals has already demonstrated significant efficacy. Ghrelin, peptide YY (PYY), cholecystokinin (CCK), and amylin are crucial in appetite regulation offering promising targets for pharmacological interventions in obesity treatment using both peptide-based and small molecule-based pharmaceuticals. Ghrelin, a sole orexigenic gut peptide, has a potential for anti-obesity therapies through various approaches, including endogenous ghrelin neutralization, ghrelin receptor antagonists, ghrelin O-acyltransferase, and functional inhibitors. Anorexigenic gut peptides, peptide YY, cholecystokinin, and amylin, have exhibited appetite-reducing effects in animal models and humans. Overcoming substantial obstacles is imperative for translating these findings into clinically effective pharmaceuticals. Peptide YY and cholecystokinin analogues, characterized by prolonged half-life and resistance to proteolytic enzymes, present viable options. Positive allosteric modulators emerge as a novel approach for modulating the cholecystokinin pathway. Amylin is currently the most promising, with both amylin analogues and dual amylin and calcitonin receptor agonists (DACRAs) progressing to advanced stages of clinical trials. Despite persistent challenges, innovative pharmaceutical strategies provide a glimpse into the future of anti-obesity therapies.
Substances chimiques
Anti-Obesity Agents
0
Cholecystokinin
9011-97-6
Ghrelin
0
Islet Amyloid Polypeptide
0
Peptide YY
106388-42-5
Appetite Depressants
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
e1243Informations de copyright
© 2024 The Author(s). Pharmacology Research & Perspectives published by British Pharmacological Society and American Society for Pharmacology and Experimental Therapeutics and John Wiley & Sons Ltd.
Références
World Health Organization. Obesity. Accessed November 7, 2023. https://www.who.int/health‐topics/obesity#tab=tab_1
Meldrum DR, Morris MA, Gambone JC. Obesity pandemic: causes, consequences, and solutions—but do we have the will? Fertil Steril. 2017;107(4):833‐839. doi:10.1016/j.fertnstert.2017.02.104
Pineda E, Sanchez‐Romero LM, Brown M, et al. Forecasting future trends in obesity across Europe: the value of improving surveillance. Obes Facts. 2018;11(5):360‐371. doi:10.1159/000492115
Kinlen D, Cody D, O'Shea D. Complications of obesity. QJM. 2018;111(7):437‐443. doi:10.1093/qjmed/hcx152
Chong B, Jayabaskaran J, Kong G, et al. Trends and predictions of malnutrition and obesity in 204 countries and territories: an analysis of the global burden of disease study 2019. EClinicalMedicine. 2023;57:101850. doi:10.1016/j.eclinm.2023.101850
Cawley J, Biener A, Meyerhoefer C, et al. Direct medical costs of obesity in the United States and the most populous states. J Manag Care Spec Pharm. 2021;27(3):354‐366. doi:10.18553/jmcp.2021.20410
d'Errico M, Pavlova M, Spandonaro F. The economic burden of obesity in Italy: a cost‐of‐illness study. Eur J Health Econ. 2022;23(2):177‐192. doi:10.1007/s10198-021-01358-1
Spanggaard M, Bøgelund M, Dirksen C, et al. The substantial costs to society associated with obesity—a Danish register‐based study based on 2002–2018 data. Expert Rev Pharmacoecon Outcomes Res. 2022;22(5):823‐833. doi:10.1080/14737167.2022.2053676
Masood B, Moorthy M. Causes of obesity: a review. Clin Med. 2023;23(4):284‐291. doi:10.7861/clinmed.2023-0168
Lin X, Li H. Obesity: epidemiology, pathophysiology, and therapeutics. Front Endocrinol. 2021;12:12. doi:10.3389/fendo.2021.706978
Alhabeeb H, AlFaiz A, Kutbi E, et al. Gut hormones in health and obesity: the upcoming role of short chain fatty acids. Nutrients. 2021;13(2):481. doi:10.3390/nu13020481
Harding SD, Sharman JL, Faccenda E, et al. The IUPHAR/BPS guide to PHARMACOLOGY in 2018: updates and expansion to encompass the new guide to IMMUNOPHARMACOLOGY. Nucleic Acids Res. 2018;46(D1):D1091‐D1106. doi:10.1093/nar/gkx1121
Alexander SPH, Christopoulos A, Davenport AP, et al. The concise guide to PHARMACOLOGY 2023/24: G protein‐coupled receptors. Br J Pharmacol. 2023;180(S2):S23‐S144. doi:10.1111/bph.16177
Amin T, Mercer JG. Hunger and satiety mechanisms and their potential exploitation in the regulation of food intake. Curr Obes Rep. 2016;5(1):106‐112. doi:10.1007/s13679-015-0184-5
Speakman JR, Elmquist JK. Obesity: an evolutionary context. Life Metabol. 2022;1(1):10‐24. doi:10.1093/lifemeta/loac002
Cifuentes L, Acosta A. Homeostatic regulation of food intake. Clin Res Hepatol Gastroenterol. 2022;46(2):101794. doi:10.1016/j.clinre.2021.101794
Schwartz MB, Just DR, Chriqui JF, Ammerman AS. Appetite self‐regulation: environmental and policy influences on eating behaviors. Obesity. 2017;25(S1):S26‐S38. doi:10.1002/oby.21770
Murphy KG, Dhillo WS, Bloom SR. Gut peptides in the regulation of food intake and energy homeostasis. Endocr Rev. 2006;27(7):719‐727. doi:10.1210/er.2006-0028
Samson WK. Neuropeptides. Encyclopedia of Neuroscience. Springer; 2009:2803‐2807. doi:10.1007/978-3-540-29678-2_3931
van der Klaauw AA. Neuropeptides in obesity and metabolic disease. Clin Chem. 2018;64(1):173‐182. doi:10.1373/clinchem.2017.281568
Pressley H, Cornelio CK, Adams EN. Setmelanotide: a novel targeted treatment for monogenic obesity. J Pharm Technol. 2022;38(6):368‐373. doi:10.1177/87551225221116010
Holzer P, Farzi A. Neuropeptides and the microbiota‐gut‐brain Axis. In: Lyte M, Cryan J, eds. Microbial Endocrinology: the Microbiota‐Gut‐Brain Axis in Health and Disease. Advances in Experimental Medicine and Biology. Springer; 2014:195‐219. doi:10.1007/978-1-4939-0897-4_9
Al‐Najim W, Docherty NG, le Roux CW. Food intake and eating behavior after bariatric surgery. Physiol Rev. 2018;98(3):1113‐1141. doi:10.1152/physrev.00021.2017
Ochner CN, Gibson C, Shanik M, Goel V, Geliebter A. Changes in neurohormonal gut peptides following bariatric surgery. Int J Obes (Lond). 2011;35(2):153‐166. doi:10.1038/ijo.2010.132
Chakhtoura M, Haber R, Ghezzawi M, Rhayem C, Tcheroyan R, Mantzoros CS. Pharmacotherapy of obesity: an update on the available medications and drugs under investigation. EClinicalMedicine. 2023;58:101882. doi:10.1016/j.eclinm.2023.101882
Müller TD, Blüher M, Tschöp MH, DiMarchi RD. Anti‐obesity drug discovery: advances and challenges. Nat Rev Drug Discov. 2022;21(3):201‐223. doi:10.1038/s41573-021-00337-8
Tan Q, Akindehin SE, Orsso CE, et al. Recent advances in Incretin‐based pharmacotherapies for the treatment of obesity and diabetes. Front Endocrinol. 2022;13:838410. doi:10.3389/fendo.2022.838410
Holst JJ. Glucagon‐like peptide‐1: are its roles as endogenous hormone and therapeutic wizard congruent? J Intern Med. 2022;291(5):557‐573. doi:10.1111/joim.13433
Holst JJ, Albrechtsen NJW, Rosenkilde MM, Deacon CF. Physiology of the Incretin hormones, GIP and GLP‐1‐regulation of release and posttranslational modifications. Comprehensive Physiology. Wiley; 2019:1339‐1381. doi:10.1002/cphy.c180013
Wang JY, Wang QW, Yang XY, et al. GLP−1 receptor agonists for the treatment of obesity: role as a promising approach. Front Endocrinol. 2023;14:1085799. doi:10.3389/fendo.2023.1085799
Buse JB, Nauck M, Forst T, et al. Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION‐6): a randomised, open‐label study. The Lancet. 2013;381(9861):117‐124. doi:10.1016/S0140-6736(12)61267-7
O'Neil PM, Birkenfeld AL, McGowan B, et al. Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double‐blind, placebo and active controlled, dose‐ranging, phase 2 trial. The Lancet. 2018;392(10148):637‐649. doi:10.1016/S0140-6736(18)31773-2
Pi‐Sunyer X, Astrup A, Fujioka K, et al. A randomized, controlled trial of 3.0 mg of Liraglutide in weight management. N Engl J Med. 2015;373(1):11‐22. doi:10.1056/NEJMoa1411892
Wadden TA, Hollander P, Klein S, et al. Weight maintenance and additional weight loss with liraglutide after low‐calorie‐diet‐induced weight loss: the SCALE maintenance randomized study. Int J Obes. 2013;37(11):1443‐1451. doi:10.1038/ijo.2013.120
Zhang R, Hou QC, Li BH, et al. Efficacy and safety of subcutaneous semaglutide in adults with overweight or obese: a subgroup meta‐analysis of randomized controlled trials. Front Endocrinol. 2023;14:1132004. doi:10.3389/fendo.2023.1132004
Finan B, Müller TD, Clemmensen C, Perez‐Tilve D, DiMarchi RD, Tschöp MH. Reappraisal of GIP pharmacology for metabolic diseases. Trends Mol Med. 2016;22(5):359‐376. doi:10.1016/j.molmed.2016.03.005
Kieffer TJ, McIntosh CH, Pederson RA. Degradation of glucose‐dependent insulinotropic polypeptide and truncated glucagon‐like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV. Endocrinology. 1995;136(8):3585‐3596. doi:10.1210/endo.136.8.7628397
Meier JJ, Nauck MA, Kranz D, et al. Secretion, degradation, and elimination of glucagon‐like peptide 1 and gastric inhibitory polypeptide in patients with chronic renal insufficiency and healthy control subjects. Diabetes. 2004;53(3):654‐662. doi:10.2337/diabetes.53.3.654
Miyawaki K, Yamada Y, Ban N, et al. Inhibition of gastric inhibitory polypeptide signaling prevents obesity. Nat Med. 2002;8(7):738‐742. doi:10.1038/nm727
Fukuda M. The role of GIP receptor in the CNS for the pathogenesis of obesity. Diabetes. 2021;70(9):1929‐1937. doi:10.2337/dbi21-0001
Mroz PA, Finan B, Gelfanov V, et al. Optimized GIP analogs promote body weight lowering in mice through GIPR agonism not antagonism. Mol Metab. 2019;20:51‐62. doi:10.1016/j.molmet.2018.12.001
Campbell JE. Targeting the GIPR for obesity: to agonize or antagonize? Potential mechanisms. Mol Metab. 2021;46:101139. doi:10.1016/j.molmet.2020.101139
Frías JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus Semaglutide once weekly in patients with type 2 diabetes. N Engl J Med. 2021;385(6):503‐515. doi:10.1056/NEJMoa2107519
Dahl D, Onishi Y, Norwood P, et al. Effect of subcutaneous Tirzepatide vs placebo added to titrated insulin glargine on glycemic control in patients with type 2 diabetes. JAMA. 2022;327(6):534. doi:10.1001/jama.2022.0078
Lin F, Yu B, Ling B, et al. Weight loss efficiency and safety of tirzepatide: a systematic review. PLoS One. 2023;18(5):e0285197. doi:10.1371/journal.pone.0285197
Coskun T, Sloop KW, Loghin C, et al. LY3298176, a novel dual GIP and GLP‐1 receptor agonist for the treatment of type 2 diabetes mellitus: from discovery to clinical proof of concept. Mol Metab. 2018;18:3‐14. doi:10.1016/j.molmet.2018.09.009
Food and Drug Administration. Orlistat (marketed as Alli and Xenical) Information. 2015 Accessed November 7, 2023. https://www.fda.gov/drugs/postmarket‐drug‐safety‐information‐patients‐and‐providers/orlistat‐marketed‐alli‐and‐xenical‐information
European medicines agency. Xenical. 2023 Accessed November 7, 2023. https://www.ema.europa.eu/en/medicines/human/EPAR/xenical
VIVUS Inc. Qsymia: Highlights of Prescribing Information. 2012 Accessed November 7, 2023. https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/022580s000lbl.pdf
European Medicines Agency. Qsiva. 2013 Accessed November 7, 2023. https://www.ema.europa.eu/en/medicines/human/EPAR/qsiva
Orexigen Therapeutics Inc. Contrave: Highlights of Prescribing Information. 2014 Accessed November 7, 2023. https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/200063s000lbl.pdf
European Medicines Agency. Mysimba. 2023 Accessed November 7, 2023. https://www.ema.europa.eu/en/medicines/human/EPAR/mysimba
European Medicines Agency. Saxenda. 2023 Accessed November 7, 2023. https://www.ema.europa.eu/en/medicines/human/EPAR/saxenda
Novo Nordisk. Saxenda: Highlights of Prescribing Information. 2014 Accessed November 7, 2023. https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/206321orig1s000lbl.pdf
Food and Drug Administration. FDA approves weight management drug for patients aged 12 and older. 2020 Accessed December 9, 2023. https://www.fda.gov/drugs/news‐events‐human‐drugs/fda‐approves‐weight‐management‐drug‐patients‐aged‐12‐and‐older
Novo Nordisk. Wegovy: Highlights of Prescribing Information. 2022 Accessed November 7, 2023. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/215256s007lbl.pdf
European Medicines Agency. Wegovy. 2023 Accessed November 7, 2023. https://www.ema.europa.eu/en/medicines/human/EPAR/wegovy
Eli Lilly and Company. Zepbound: Highlights of Prescribing Information. 2023 Accessed November 7, 2023. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/217806s000lbl.pdf
European Medicines Agency. Mounjaro—opinion on variation to marketing authorisation. 2023 Accessed December 7, 2023.
Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K. Ghrelin is a growth‐hormone‐releasing acylated peptide from stomach. Nature. 1999;402(6762):656‐660. doi:10.1038/45230
Tschöp M, Smiley DL, Heiman ML. Ghrelin induces adiposity in rodents. Nature. 2000;407(6806):908‐913. doi:10.1038/35038090
Wren AM, Seal LJ, Cohen MA, et al. Ghrelin enhances appetite and increases food intake in humans. J Clin Endocrinol Metab. 2001;86(12):5992. doi:10.1210/jcem.86.12.8111
Tschöp M, Weyer C, Tataranni PA, Devanarayan V, Ravussin E, Heiman ML. Circulating ghrelin levels are decreased in human obesity. Diabetes. 2001;50(4):707‐709. doi:10.2337/diabetes.50.4.707
Yang J, Brown MS, Liang G, Grishin NV, Goldstein JL. Identification of the acyltransferase that Octanoylates ghrelin, an appetite‐stimulating peptide hormone. Cell. 2008;132(3):387‐396. doi:10.1016/j.cell.2008.01.017
Müller TD, Nogueiras R, Andermann ML, et al. Ghrelin. Mol Metab. 2015;4(6):437‐460. doi:10.1016/j.molmet.2015.03.005
Koutouratsas T, Kalli T, Karamanolis G, Gazouli M. Contribution of ghrelin to functional gastrointestinal disorders' pathogenesis. World J Gastroenterol. 2019;25(5):539‐551. doi:10.3748/wjg.v25.i5.539
Pemberton CJ, Richards AM. Biochemistry of ghrelin precursor peptides. Vitam Horm. 2007;77:13‐30. doi:10.1016/S0083-6729(06)77002-9
Young E, Jialal I. Biochemistry, ghrelin. StatPearls. 2023; Accessed November 7, 2023. https://www.ncbi.nlm.nih.gov/books/NBK547692/
Deschaine SL, Leggio L. From “hunger hormone” to “It's complicated”: ghrelin beyond feeding control. Phys Ther. 2022;37(1):5‐15. doi:10.1152/physiol.00024.2021
Yanagi S, Sato T, Kangawa K, Nakazato M. The homeostatic force of ghrelin. Cell Metab. 2018;27(4):786‐804. doi:10.1016/j.cmet.2018.02.008
Tauber M, Coupaye M, Diene G, Molinas C, Valette M, Beauloye V. Prader‐Willi syndrome: A model for understanding the ghrelin system. J Neuroendocrinol. 2019;31(7):e12728. doi:10.1111/jne.12728
Jiao ZT, Luo Q. Molecular mechanisms and health benefits of ghrelin: a narrative review. Nutrients. 2022;14(19):4191. doi:10.3390/nu14194191
Zhang L, Hernandez‐Sanchez D, Herzog H. Regulation of feeding related behaviours by arcuate neuropeptide Y neurons. Endocrinology. 2019;160(6):1411‐1420. doi:10.1210/en.2019-00056
Malik S, McGlone F, Bedrossian D, Dagher A. Ghrelin modulates brain activity in areas that control appetitive behavior. Cell Metab. 2008;7(5):400‐409. doi:10.1016/j.cmet.2008.03.007
Goldstone AP, Prechtl CG, Scholtz S, et al. Ghrelin mimics fasting to enhance human hedonic, orbitofrontal cortex, and hippocampal responses to food. Am J Clin Nutr. 2014;99(6):1319‐1330. doi:10.3945/ajcn.113.075291
Veldhuis JD, Bowers CY. Integrating GHS into the ghrelin system. Int J Pept. 2010;2010:1‐40. doi:10.1155/2010/879503
Roh E, Choi KM. Hormonal gut–brain signaling for the treatment of obesity. Int J Mol Sci. 2023;24(4):3384. doi:10.3390/ijms24043384
Varela L, Horvath TL. Leptin and insulin pathways in POMC and AgRP neurons that modulate energy balance and glucose homeostasis. EMBO Rep. 2012;13(12):1079‐1086. doi:10.1038/embor.2012.174
Dong Y, Carty J, Goldstein N, et al. Time and metabolic state‐dependent effects of GLP‐1R agonists on NPY/AgRP and POMC neuronal activity in vivo. Mol Metab. 2021;54:101352. doi:10.1016/j.molmet.2021.101352
Acuna‐Goycolea C, van den Pol AN. Peptide YY (3‐36) inhibits both Anorexigenic proopiomelanocortin and Orexigenic neuropeptide Y neurons: implications for hypothalamic regulation of energy homeostasis. J Neurosci. 2005;25(45):10510‐10519. doi:10.1523/JNEUROSCI.2552-05.2005
Jais A, Brüning JC. Arcuate nucleus‐dependent regulation of metabolism—pathways to obesity and diabetes mellitus. Endocr Rev. 2022;43(2):314‐328. doi:10.1210/endrev/bnab025
Lutz TA. Creating the amylin story. Appetite. 2022;172:105965. doi:10.1016/j.appet.2022.105965
Cummings DE, Purnell JQ, Frayo RS, Schmidova K, Wisse BE, Weigle DS. A Preprandial rise in plasma ghrelin levels suggests a role in meal initiation in humans. Diabetes. 2001;50(8):1714‐1719. doi:10.2337/diabetes.50.8.1714
Sanger GJ, Broad J, Callaghan B, Furness JB. Ghrelin and motilin control systems in GI physiology and therapeutics. Handb Exp Pharmacol. 2016;239:379‐416. doi:10.1007/164_2016_104
Adamska‐Patruno E, Ostrowska L, Goscik J, et al. The differences in postprandial serum concentrations of peptides that regulate satiety/hunger and metabolism after various meal intake, in men with Normal vs. Excessive BMI. Nutrients. 2019;11(3):493. doi:10.3390/nu11030493
Schmid SM, Hallschmid M, Jauch‐Chara K, Born J, Schultes B. A single night of sleep deprivation increases ghrelin levels and feelings of hunger in normal‐weight healthy men. J Sleep Res. 2008;17(3):331‐334. doi:10.1111/j.1365-2869.2008.00662.x
van Egmond LT, Meth EMS, Engström J, et al. Effects of acute sleep loss on leptin, ghrelin, and adiponectin in adults with healthy weight and obesity: a laboratory study. Obesity. 2023;31(3):635‐641. doi:10.1002/oby.23616
Bouillon‐Minois JB, Trousselard M, Thivel D, et al. Ghrelin as a biomarker of stress: a systematic review and meta‐analysis. Nutrients. 2021;13(3):784. doi:10.3390/nu13030784
Abizaid A. Stress and obesity: the ghrelin connection. J Neuroendocrinol. 2019;31(7):e12693. doi:10.1111/jne.12693
Wang Y, Wu Q, Zhou Q, et al. Circulating acyl and des‐acyl ghrelin levels in obese adults: a systematic review and meta‐analysis. Sci Rep. 2022;12(1):2679. doi:10.1038/s41598-022-06636-3
Alvarez‐Castro P, Pena L, Cordido F. Ghrelin in obesity, physiological and pharmacological considerations. Mini‐Rev Med Chem. 2013;13(4):541‐552. doi:10.2174/1389557511313040007
Giorgioni G, Del Bello F, Quaglia W, et al. Advances in the development of nonpeptide Small molecules targeting ghrelin receptor. J Med Chem. 2022;65(4):3098‐3118. doi:10.1021/acs.jmedchem.1c02191
Colldén G, Tschöp M, Müller T. Therapeutic potential of targeting the ghrelin pathway. Int J Mol Sci. 2017;18(4):798. doi:10.3390/ijms18040798
Buckinx A, De Bundel D, Kooijman R, Smolders I. Targeting the ghrelin receptor as a novel therapeutic option for epilepsy. Biomedicine. 2021;10(1):53. doi:10.3390/biomedicines10010053
Merritt CR, Garcia EJ, Brehm VD, et al. Ghrelin receptor antagonist JMV2959 blunts cocaine and oxycodone drug‐seeking, but not self‐administration, in male rats. Front Pharmacol. 2023;14:1268366. doi:10.3389/fphar.2023.1268366
European Medicines Agency. EU/3/17/1882—orphan designation for treatment of growth hormone deficiency. 2017 Accessed November 7, 2023.
Wakabayashi H, Arai H, Inui A. Anamorelin in Japanese patients with cancer cachexia: an update. Curr Opin Support Palliat Care. 2023;17(3):162‐167. doi:10.1097/SPC.0000000000000658
Liang Y, Yin W, Yin Y, Zhang W. Ghrelin based therapy of metabolic diseases. Curr Med Chem. 2021;28(13):2565‐2576. doi:10.2174/0929867327666200615152804
Liu D, Li S. LEAP2: next game‐changer of pharmacotherapy for overweight and obesity? Cell Rep Med. 2022;3(4):100612. doi:10.1016/j.xcrm.2022.100612
Allas S, Caixàs A, Poitou C, et al. AZP‐531, an unacylated ghrelin analog, improves food‐related behavior in patients with Prader‐Willi syndrome: a randomized placebo‐controlled trial. PLoS One. 2018;13(1):e0190849. doi:10.1371/journal.pone.0190849
Henry RK. Macimorelin acetate for the diagnosis of childhood‐onset growth hormone deficiency. Eur Endocrinol. 2022;18(2):84. doi:10.17925/EE.2022.18.2.84
Andrade S, Pinho F, Ribeiro A, et al. Immunization against active ghrelin using virus‐like particles for obesity treatment. Curr Pharm Des. 2013;19(36):6551‐6558. doi:10.2174/13816128113199990506
Zorrilla EP, Iwasaki S, Moss JA, et al. Vaccination against weight gain. Proc Natl Acad Sci U S A. 2006;103(35):13226‐13231. doi:10.1073/pnas.0605376103
Vizcarra JA, Kirby JD, Kim SK, Galyean ML. Active immunization against ghrelin decreases weight gain and alters plasma concentrations of growth hormone in growing pigs. Domest Anim Endocrinol. 2007;33(2):176‐189. doi:10.1016/j.domaniend.2006.05.005
Azegami T, Yuki Y, Sawada S, et al. Nanogel‐based nasal ghrelin vaccine prevents obesity. Mucosal Immunol. 2017;10(5):1351‐1360. doi:10.1038/mi.2016.137
Rotkvic V, Altabas V. Anti‐ghrelin antibodies in appetite suppression: recent advances in obesity pharmacotherapy. Immunotargets Ther. 2015;4:123‐130. doi:10.2147/ITT.S60398
AdisInsight. CYT 009 GhrQb: Drug Profile. 2006 Accessed November 7, 2023. https://adisinsight.springer.com/drugs/800023624#disabled
Becskei C, Bilik KU, Klussmann S, Jarosch F, Lutz TA, Riediger T. The anti‐ghrelin Spiegelmer NOX‐B11‐3 blocks ghrelin‐ but not fasting‐induced neuronal activation in the hypothalamic arcuate nucleus. J Neuroendocrinol. 2008;20(1):85‐92. doi:10.1111/j.1365-2826.2007.01619.x
Moran TH, Dailey MJ. Gut peptides: targets for Antiobesity drug development? Endocrinology. 2009;150(6):2526‐2530. doi:10.1210/en.2009-0003
Esler WP, Rudolph J, Claus TH, et al. Small‐molecule ghrelin receptor antagonists improve glucose tolerance, suppress appetite, and promote weight loss. Endocrinology. 2007;148(11):5175‐5185. doi:10.1210/en.2007-0239
Zhao J, Du X, Chen M, Zhu S. Growth hormone Secretagogue receptor 1A antagonist JMV2959 effectively prevents morphine memory reconsolidation and relapse. Front Pharmacol. 2021;12:718615. doi:10.3389/fphar.2021.718615
Ge X, Yang H, Bednarek MA, et al. LEAP2 is an endogenous antagonist of the ghrelin receptor. Cell Metab. 2018;27(2):461‐469. doi:10.1016/j.cmet.2017.10.016
Lu X, Huang L, Huang Z, Feng D, Clark RJ, Chen C. LEAP‐2: an emerging endogenous ghrelin receptor antagonist in the pathophysiology of obesity. Front Endocrinol. 2021;12:717544. doi:10.3389/fendo.2021.717544
Hagemann CA, Jensen MS, Holm S, et al. LEAP2 reduces postprandial glucose excursions and ad libitum food intake in healthy men. Cell Rep Med. 2022;3(4):100582. doi:10.1016/j.xcrm.2022.100582
Moose JE, Leets KA, Mate NA, Chisholm JD, Hougland JL. An overview of ghrelin O ‐acyltransferase inhibitors: a literature and patent review for 2010‐2019. Expert Opin Ther Pat. 2020;30(8):581‐593. doi:10.1080/13543776.2020.1776263
University College L. BARI‐INSIGHT: A Double‐Blind, Placebo‐Controlled, Within‐Subject, Cross‐over Mechanistic Study Investigating the Role of Ghrelin in Regulating Appetite and Energy Intake in Patients Following Bariatric Surgery. 2020 Accessed December 7, 2023. https://clinicaltrials.gov/study/NCT03641417
National Institute on Drug Abuse (NIDA). Manipulating Ghrelin Signaling Via GOAT Inhibition in Alcohol Use Disorder. 2023 https://clinicaltrials.gov/study/NCT03896516
Miller JL, Lacroix A, Bird LM, et al. The efficacy, safety, and pharmacology of a ghrelin O‐acyltransferase inhibitor for the treatment of Prader‐Willi syndrome. J Clin Endocrinol Metab. 2022;107(6):e2373‐e2380. doi:10.1210/clinem/dgac105
Bianzano S, Henrich A, Herich L, et al. Efficacy and safety of the ghrelin‐O‐acyltransferase inhibitor BI 1356225 in overweight/obesity: data from two phase I, randomised, placebo‐controlled studies. Metabolism. 2023;143:155550. doi:10.1016/j.metabol.2023.155550
Millendo Therapeutics SAS. A Phase 2b/3 Study to Evaluate the Safety, Tolerability, and Effects of Livoletide (AZP‐531), an Unacylated Ghrelin Analogue, on Food‐Related Behaviors in Patients With Prader‐Willi Syndrome. 2021 Accessed November 7, 2023. https://clinicaltrials.gov/study/NCT03790865
Strong T. Millendo Discontinues Livoletide Program for PWS. Foundation for Prader‐Willy Research; 2020 Accessed December 7, 2023. https://www.fpwr.org/blog/millendo‐discontinues‐livoletide‐program‐for‐pws
Ibrahim Abdalla MM. Ghrelin – physiological functions and regulation. Eur Endocrinol. 2015;11(2):90. doi:10.17925/EE.2015.11.02.90
Asakawa A. Stomach regulates energy balance via acylated ghrelin and desacyl ghrelin. Gut. 2005;54(1):18‐24. doi:10.1136/gut.2004.038737
Wren AM, Bloom SR. Gut hormones and appetite control. Gastroenterology. 2007;132(6):2116‐2130. doi:10.1053/j.gastro.2007.03.048
Pradhan G, Samson SL, Sun Y. Ghrelin. Curr Opin Clin Nutr Metab Care. 2013;16(6):619‐624. doi:10.1097/MCO.0b013e328365b9be
Makris M, Alexandrou A, Papatsoutsos E, et al. Ghrelin and obesity: identifying gaps and dispelling myths. A reappraisal. In Vivo. 2017;31(6):1047‐1050. doi:10.21873/invivo.11168
Vona‐Davis L, McFadden D. NPY family of hormones: clinical relevance and potential use in gastrointestinal disease. Curr Top Med Chem. 2007;7(17):1710‐1720. doi:10.2174/156802607782340966
Tatemoto K, Mutt V. Isolation of two novel candidate hormones using a chemical method for finding naturally occurring polypeptides. Nature. 1980;285(5764):417‐418. doi:10.1038/285417a0
Lafferty RA, Flatt PR, Irwin N. Emerging therapeutic potential for peptide YY for obesity‐diabetes. Peptides. 2018;100:269‐274. doi:10.1016/j.peptides.2017.11.005
Karra E, Chandarana K, Batterham RL. The role of peptide YY in appetite regulation and obesity. J Physiol. 2009;587(1):19‐25. doi:10.1113/jphysiol.2008.164269
Chen W, Binbin G, Lidan S, Qiang Z, Jing H. Evolution of peptide YY analogs for the management of type 2 diabetes and obesity. Bioorg Chem. 2023;140:106808. doi:10.1016/j.bioorg.2023.106808
Deacon CF. Peptide degradation and the role of DPP‐4 inhibitors in the treatment of type 2 diabetes. Peptides. 2018;100:150‐157. doi:10.1016/j.peptides.2017.10.011
Deacon CF. Physiology and pharmacology of DPP‐4 in glucose homeostasis and the treatment of type 2 diabetes. Front Endocrinol. 2019;10:80. doi:10.3389/fendo.2019.00080
Batterham RL, Heffron H, Kapoor S, et al. Critical role for peptide YY in protein‐mediated satiation and body‐weight regulation. Cell Metab. 2006;4(3):223‐233. doi:10.1016/j.cmet.2006.08.001
Batterham RL, Cowley MA, Small CJ, et al. Gut hormone PYY3‐36 physiologically inhibits food intake. Nature. 2002;418(6898):650‐654. doi:10.1038/nature00887
Penín M, Perez Fontán M, Garcia Buela J, et al. PYY(1‐36) and PYY(3‐36) secretory response after a mixed meal in healthy individuals. Endocrinol Nutr. 2008;55(8):333‐339. doi:10.1016/S1575-0922(08)72793-1
le Roux CW, Batterham RL, Aylwin SJB, et al. Attenuated peptide YY release in obese subjects is associated with reduced satiety. Endocrinology. 2006;147(1):3‐8. doi:10.1210/en.2005-0972
Persaud SJ, Bewick GA. Peptide YY: more than just an appetite regulator. Diabetologia. 2014;57(9):1762‐1769. doi:10.1007/s00125-014-3292-y
Stadlbauer U, Woods SC, Langhans W, Meyer U. PYY3–36: beyond food intake. Front Neuroendocrinol. 2015;38:1‐11. doi:10.1016/j.yfrne.2014.12.003
Koliaki C, Liatis S, Dalamaga M, Kokkinos A. The implication of gut hormones in the regulation of energy homeostasis and their role in the pathophysiology of obesity. Curr Obes Rep. 2020;9(3):255‐271. doi:10.1007/s13679-020-00396-9
Unniappan S, McIntosh CHS, Demuth HU, Heiser U, Wolf R, Kieffer TJ. Effects of dipeptidyl peptidase IV on the satiety actions of peptide YY. Diabetologia. 2006;49(8):1915‐1923. doi:10.1007/s00125-006-0310-8
Batterham RL, Bloom SR. The gut hormone peptide YY regulates appetite. Ann N Y Acad Sci. 2003;994(1):162‐168. doi:10.1111/j.1749-6632.2003.tb03176.x
Khan D, Vasu S, Moffett RC, Irwin N, Flatt PR. Islet distribution of peptide YY and its regulatory role in primary mouse islets and immortalised rodent and human beta‐cell function and survival. Mol Cell Endocrinol. 2016;436:102‐113. doi:10.1016/j.mce.2016.07.020
Sam AH, Gunner DJ, King A, et al. Selective ablation of peptide YY cells in adult mice reveals their role in Beta cell survival. Gastroenterology. 2012;143(2):459‐468. doi:10.1053/j.gastro.2012.04.047
Batterham RL, Cohen MA, Ellis SM, et al. Inhibition of food intake in obese subjects by peptide YY 3–36. N Engl J Med. 2003;349(10):941‐948. doi:10.1056/NEJMoa030204
Zac‐Varghese S, De Silva A, Bloom SR. Translational studies on PYY as a novel target in obesity. Curr Opin Pharmacol. 2011;11(6):582‐585. doi:10.1016/j.coph.2011.10.001
Sloth B, Davidsen L, Holst JJ, Flint A, Astrup A. Effect of subcutaneous injections of PYY 1‐36 and PYY 3‐36 on appetite, ad libitum energy intake, and plasma free fatty acid concentration in obese males. Am J Physiol Endocrinol Metabol. 2007;293(2):E604‐E609. doi:10.1152/ajpendo.00153.2007
Gantz I, Erondu N, Mallick M, et al. Efficacy and safety of intranasal peptide YY3–36 for weight reduction in obese adults. J Clin Endocrinol Metab. 2007;92(5):1754‐1757. doi:10.1210/jc.2006-1806
Poulsen C, Pedersen MØ, Wahlund PO, et al. Rational development of stable PYY3–36 peptide Y2 receptor agonists. Pharm Res. 2021;38(8):1369‐1385. doi:10.1007/s11095-021-03077-x
Østergaard S, Kofoed J, Paulsson JF, Madsen KG, Jorgensen R, Wulff BS. Design of Y 2 receptor selective and Proteolytically stable PYY 3–36 analogues. J Med Chem. 2018;61(23):10519‐10530. doi:10.1021/acs.jmedchem.8b01046
DeCarr LB, Buckholz TM, Coish PDG, et al. Identification of selective neuropeptide Y2 peptide agonists. Bioorg Med Chem Lett. 2007;17(2):538‐541. doi:10.1016/j.bmcl.2006.10.007
Pedersen SL, Holst B, Vrang N, Jensen KJ. Modifying the conserved C ‐terminal tyrosine of the peptide hormone PYY3‐36 to improve Y2 receptor selectivity. J Pept Sci. 2009;15(11):753‐759. doi:10.1002/psc.1170
Jones ES, Nunn N, Chambers AP, Østergaard S, Wulff BS, Luckman SM. Modified peptide YY molecule attenuates the activity of NPY/AgRP neurons and reduces food intake in male mice. Endocrinology. 2019;160(11):2737‐2747. doi:10.1210/en.2019-00100
Oertel M, Theisen J, Ecker K, et al. Effects of a combinatory treatment with semaglutide and a NPY Y2 receptor selective PYY 3‐36 analogue in diet‐induced obese rats: surpassing bariatric surgery? Endocrine Abstracts. 2023;2. doi:10.1530/endoabs.90.P326
Rangwala SM, D'Aquino K, Zhang YM, et al. A long‐acting PYY3–36 analog mediates robust anorectic efficacy with minimal emesis in nonhuman primates. Cell Metab. 2019;29(4):837‐843.e5. doi:10.1016/j.cmet.2019.01.017
Novo Nordisk A/S. A Research Study of NNC0165‐1562 and Semaglutide in People Who Are Overweight or Obese. 2021 Accessed December 7, 2023. https://clinicaltrials.gov/study/NCT03574584
Hemmingsen MA. Diabetes fusion tablet and potential obesity drug dropped by Novo Nordisk. MedWatch. 2023; Accessed December 7, 2023. https://medwatch.com/News/Pharma___Biotech/article16344607.ece
Liddle RA. Cholecystokinin cells. Annu Rev Physiol. 1997;59(1):221‐242. doi:10.1146/annurev.physiol.59.1.221
Beinfeld MC. Biosynthesis and processing of pro CCK: recent progress and future challenges. Life Sci. 2003;72(7):747‐757. doi:10.1016/S0024-3205(02)02330-5
Anyetei‐Anum EN, Blum A, Seidah NG, Beinfeld MC. Prohormone convertase 7 is necessary for the normal processing of cholecystokinin in mouse brain. Biochem Biophys Res Commun. 2017;482(4):1190‐1193. doi:10.1016/j.bbrc.2016.12.010
Liddle RA, Lamont JT, Grover S. Physiology of cholecystokinin. UpToDate. 2023; Accessed December 7, 2023. https://www.uptodate.com/contents/physiology‐of‐cholecystokinin
Miller LJ, Harikumar KG, Wootten D, Sexton PM. Roles of cholecystokinin in the nutritional continuum. Physiology and potential therapeutics. Front Endocrinol. 2021;12:684656. doi:10.3389/fendo.2021.684656
Rehfeld JF. Cholecystokinin—from local gut hormone to ubiquitous messenger. Front Endocrinol. 2017;8:47. doi:10.3389/fendo.2017.00047
Kato T, Harada N, Ikeguchi‐Ogura E, et al. Gene expression of nutrient‐sensing molecules in I cells of CCK reporter male mice. J Mol Endocrinol. 2021;66(1):11‐22. doi:10.1530/JME-20-0134
Moris JM, Heinold C, Blades A, Koh Y. Nutrient‐based appetite regulation. J Obes Metab Syndr. 2022;31(2):161‐168. doi:10.7570/jomes22031
Cawthon CR, de La Serre CB. The critical role of CCK in the regulation of food intake and diet‐induced obesity. Peptides. 2021;138:170492. doi:10.1016/j.peptides.2020.170492
Zeng Q, Ou L, Wang W, Guo DY. Gastrin, cholecystokinin, signaling, and biological activities in cellular processes. Front Endocrinol. 2020;11:112. doi:10.3389/fendo.2020.00112
Pathak V, Flatt PR, Irwin N. Cholecystokinin (CCK) and related adjunct peptide therapies for the treatment of obesity and type 2 diabetes. Peptides. 2018;100:229‐235. doi:10.1016/j.peptides.2017.09.007
Bernard A, Danigo A, Bourthoumieu S, et al. The cholecystokinin type 2 receptor, a pharmacological target for pain management. Pharmaceuticals. 2021;14(11):1185. doi:10.3390/ph14111185
Lavine JA, Raess PW, Stapleton DS, et al. Cholecystokinin is up‐regulated in obese mouse islets and expands β‐cell mass by increasing β‐cell survival. Endocrinology. 2010;151(8):3577‐3588. doi:10.1210/en.2010-0233
Gibbs J, Young RC, Smith GP. Cholecystokinin elicits satiety in rats with open gastric fistulas. Nature. 1973;245(5424):323‐325. doi:10.1038/245323a0
Koszycki JBD. Cholecystokinin and panic disorder: past and future clinical research strategies. Scand J Clin Lab Invest. 2001;61(234):19‐27. doi:10.1080/clb.61.234.19.27
Irwin N, Frizelle P, O'Harte FPM, Flatt PR. (pGlu‐Gln)‐CCK‐8[mPEG]: a novel, long‐acting, mini‐PEGylated cholecystokinin (CCK) agonist that improves metabolic status in dietary‐induced diabetes. Biochim Biophys Acta. 2013;1830(8):4009‐4016. doi:10.1016/j.bbagen.2013.04.004
Irwin N, Frizelle P, Montgomery IA, Moffett RC, O'Harte FPM, Flatt PR. Beneficial effects of the novel cholecystokinin agonist (pGlu‐Gln)‐CCK‐8 in mouse models of obesity/diabetes. Diabetologia. 2012;55(10):2747‐2758. doi:10.1007/s00125-012-2654-6
Christoffersen BØ, Skyggebjerg RB, Bugge A, et al. Long‐acting CCK analogue NN9056 lowers food intake and body weight in obese Göttingen Minipigs. Int J Obes (Lond). 2020;44(2):447‐456. doi:10.1038/s41366-019-0386-0
Berger R, Zhu C, Hansen AR, et al. 2‐substituted piperazine‐derived imidazole carboxamides as potent and selective CCK1R agonists for the treatment of obesity. Bioorg Med Chem Lett. 2008;18(17):4833‐4837. doi:10.1016/j.bmcl.2008.07.083
Zhu C, Hansen AR, Bateman T, et al. Discovery of imidazole carboxamides as potent and selective CCK1R agonists. Bioorg Med Chem Lett. 2008;18(15):4393‐4396. doi:10.1016/j.bmcl.2008.06.057
Aquino CJ, Armour DR, Berman JM, et al. Discovery of 1,5‐Benzodiazepines with Peripheral Cholecystokinin (CCK‐A) Receptor Agonist Activity. 1. Optimization of the Agonist “Trigger”. J Med Chem. 1996;39(2):562‐569. doi:10.1021/jm950626d
Jordan J, Greenway F, Leiter L, et al. Stimulation of cholecystokinin‐a receptors with GI181771X does not cause weight loss in overweight or obese patients. Clin Pharmacol Ther. 2008;83(2):281‐287. doi:10.1038/sj.clpt.6100272
Harikumar KG, Coudrat T, Desai AJ, et al. Discovery of a positive allosteric modulator of cholecystokinin action at CCK1R in Normal and elevated cholesterol. Front Endocrinol. 2021;12:789957. doi:10.3389/fendo.2021.789957
Dengler DG, Sun Q, Harikumar KG, Miller LJ, Sergienko EA. Screening for positive allosteric modulators of cholecystokinin type 1 receptor potentially useful for management of obesity. SLAS Discov. 2022;27(7):384‐394. doi:10.1016/j.slasd.2022.07.001
Ling W, Huang YM, Qiao YC, Zhang XX, Zhao HL. Human amylin: from pathology to physiology and pharmacology. Curr Protein Pept Sci. 2019;20(9):944‐957. doi:10.2174/1389203720666190328111833
Hay DL, Chen S, Lutz TA, Parkes DG, Roth JD. Amylin: pharmacology, physiology, and clinical potential. Pharmacol Rev. 2015;67(3):564‐600. doi:10.1124/pr.115.010629
Dehestani B, Stratford NR, Roux CW l. Amylin as a future obesity treatment. J Obes Metab Syndr. 2021;30(4):320‐325. doi:10.7570/jomes21071
Mathiesen DS, Lund A, Vilsbøll T, Knop FK, Bagger JI. Amylin and calcitonin: potential therapeutic strategies to reduce body weight and liver fat. Front Endocrinol. 2021;11:617400. doi:10.3389/fendo.2020.617400
Boccia L, Gamakharia S, Coester B, Whiting L, Lutz TA, Le Foll C. Amylin brain circuitry. Peptides. 2020;132:170366. doi:10.1016/j.peptides.2020.170366
Bailey R, Walker C, Ferner A, et al. Pharmacological characterization of rat amylin receptors: implications for the identification of amylin receptor subtypes. Br J Pharmacol. 2012;166(1):151‐167. doi:10.1111/j.1476-5381.2011.01717.x
Gingell J, Simms J, Barwell J, et al. An allosteric role for receptor activity‐modifying proteins in defining GPCR pharmacology. Cell Discov. 2016;2(1):16012. doi:10.1038/celldisc.2016.12
Boyle CN, Lutz TA, Le Foll C. Amylin – its role in the homeostatic and hedonic control of eating and recent developments of amylin analogs to treat obesity. Mol Metab. 2018;8:203‐210. doi:10.1016/j.molmet.2017.11.009
Boyle CN, Zheng Y, Lutz TA. Mediators of amylin action in metabolic control. J Clin Med. 2022;11(8):2207. doi:10.3390/jcm11082207
Mietlicki‐Baase EG. Amylin‐mediated control of glycemia, energy balance, and cognition. Physiol Behav. 2016;162:130‐140. doi:10.1016/j.physbeh.2016.02.034
Arnelo U, Permert J, Adrian TE, Larsson J, Westermark P, Reidelberger RD. Chronic infusion of islet amyloid polypeptide causes anorexia in rats. Am J Physiol Regul Integr Comp Physiol. 1996;271(6):R1654‐R1659. doi:10.1152/ajpregu.1996.271.6.R1654
Lutz T. Amylin decreases meal size in rats. Physiol Behav. 1995;58(6):1197‐1202. doi:10.1016/0031-9384(95)02067-5
Roth JD, Hughes H, Kendall E, Baron AD, Anderson CM. Antiobesity effects of the β‐cell hormone amylin in diet‐induced obese rats: effects on food intake, body weight, composition, energy expenditure, and gene expression. Endocrinology. 2006;147(12):5855‐5864. doi:10.1210/en.2006-0393
Bower RL, Hay DL. Amylin structure–function relationships and receptor pharmacology: implications for amylin mimetic drug development. Br J Pharmacol. 2016;173(12):1883‐1898. doi:10.1111/bph.13496
Ritzel RA, Meier JJ, Lin CY, Veldhuis JD, Butler PC. Human islet amyloid polypeptide oligomers disrupt cell coupling, induce apoptosis, and impair insulin secretion in isolated human islets. Diabetes. 2007;56(1):65‐71. doi:10.2337/db06-0734
Ryan GJ, Jobe LJ, Martin R. Pramlintide in the treatment of type 1 and type 2 diabetes mellitus. Clin Ther. 2005;27(10):1500‐1512. doi:10.1016/j.clinthera.2005.10.009
Safaeian L, Shafiee F, Naderi M. Pramlintide: an amylin analogue protects endothelial cells against oxidative stress through regulating oxidative markers and NF‐κb expression. Int J Prev Med. 2022;13:20. doi:10.4103/ijpvm.IJPVM_425_20
McQueen J. Pramlintide acetate. Am J Health‐Syst Pharm. 2005;62(22):2363‐2372. doi:10.2146/ajhp050341
Baron M. Amylin withdraws application for Symlin in Europe. MarketWatch. 2022; Accessed December 7, 2023. https://www.marketwatch.com/story/amylin‐withdraws‐application‐for‐symlin‐in‐europe
Brusegan A, McKay G, Llano A. Pramlintide. Practical Diabetes. 2020;37(5):194‐195. doi:10.1002/pdi.2300
Hollander P, Maggs DG, Ruggles JA, et al. Effect of Pramlintide on weight in overweight and obese insulin‐treated type 2 diabetes patients. Obes Res. 2004;12(4):661‐668. doi:10.1038/oby.2004.76
Zakariassen HL, John LM, Lutz TA. Central control of energy balance by amylin and calcitonin receptor agonists and their potential for treatment of metabolic diseases. Basic Clin Pharmacol Toxicol. 2020;127(3):163‐177. doi:10.1111/bcpt.13427
Skarbaliene J, Just R. Anti‐diabetic effects of novel long‐acting amylin analogues ZP4982 and ZP5461 in ZDF rats. American Diabetes Association's (ADA) 76th Scientific Sessions (Online). Published online 2046. Accessed December 7, 2023. https://static1.squarespace.com/static/58983777d1758e28995640b4/t/5d4953643b48f80001ed9c5a/1565086566205/Jolanta+Skarbaliene+ADA+poster+Anti‐diabetic+effects+of+novel+long‐acting+amylin+analogues.pdf
AdisInsight. ZP 4982. 2023 Accessed December 7, 2023. https://adisinsight.springer.com/drugs/800045554
Boehringer Ingelheim. Evaluation of Safety and Tolerability of Single Rising Doses of BI 473494 in Healthy Subjects. 2022 Accessed December 7, 2023. clinicaltrials.gov. https://clinicaltrials.gov/study/NCT03195088?tab=results
Taylor P. Boehringer shows its hand in obesity. PharmaPhorum. 2023;10: Accessed December 7, 2023. https://pharmaphorum.com/news/boehringer‐shows‐its‐hand‐obesity
BI 473494. AdisInsight. 2018 Accessed December 7, 2023. https://adisinsight.springer.com/drugs/800049758
Zaeland Pharma. Zealand pharma regains worldwide rights to amylin analog program from Boehringer Ingelheim. GlobalNewswire. 2020; Accessed December 7, 2023. https://www.globenewswire.com/news‐release/2020/03/20/2004337/0/en/Zealand‐Pharma‐regains‐worldwide‐rights‐to‐Amylin‐analog‐program‐from‐Boehringer‐Ingelheim.html
Zealand Pharma. Shaping the future management of obesity. Zealand Pharma Obesity R&D Event. 2023 Accessed December 9, 2023. https://www.zealandpharma.com/wp‐content/uploads/2023/12/Zealand‐Pharma‐Obesity‐RD‐Event‐5‐Dec‐23.pdf
Olsen MB, Hövelmann U, Griffin J, et al. 92‐LB: safety, tolerability, and clinical effects of ZP8396, a novel long‐acting amylin analog—a single ascending dose trial. Diabetes. 2023;72(Supplement_1). https://www.zealandpharma.com/media/eb1azc1d/zp8396‐phase1‐mad‐part‐1‐obesityweek‐2023.pdf
Gydesen S, Andreassen KV, Hjuler ST, Christensen JM, Karsdal MA, Henriksen K. KBP‐088, a novel DACRA with prolonged receptor activation, is superior to davalintide in terms of efficacy on body weight. Am J Physiol Endocrinol Metab. 2016;310(10):E821‐E827. doi:10.1152/ajpendo.00514.2015
Larsen AT, Sonne N, Andreassen KV, Karsdal MA, Henriksen K. The calcitonin receptor plays a major role in glucose regulation as a function of dual amylin and calcitonin receptor agonist therapy. J Pharmacol Exp Ther. 2020;374(1):74‐83. doi:10.1124/jpet.119.263392
Sonne N, Larsen AT, Karsdal MA, Henriksen K. The impact of exposure profile on the efficacy of dual amylin and calcitonin receptor agonist therapy. Biomedicine. 2022;10(10):2365. doi:10.3390/biomedicines10102365
Sonne N, Larsen AT, Andreassen KV, Karsdal MA, Henriksen K. The dual amylin and calcitonin receptor agonist, KBP‐066, induces an equally potent weight loss across a Broad dose range while higher doses may further improve insulin action. J Pharmacol Exp Ther. 2020;373(1):92‐102. doi:10.1124/jpet.119.263723
Andreassen KV, Larsen AT, Sonne N, Mohamed KE, Karsdal MA, Henriksen K. KBP‐066A, a long‐acting dual amylin and calcitonin receptor agonist, induces weight loss and improves glycemic control in obese and diabetic rats. Mol Metab. 2021;53:101282. doi:10.1016/j.molmet.2021.101282
Larsen AT, Sonne N, Andreassen KV, Gehring K, Karsdal MA, Henriksen K. The dual amylin and calcitonin receptor agonist KBP‐088 induces weight loss and improves insulin sensitivity superior to chronic amylin therapy. J Pharmacol Exp Ther. 2019;370(1):35‐43. doi:10.1124/jpet.119.257576
Thorsø Larsen A, Karsdal MA, Henriksen K. Treatment sequencing using the dual amylin and calcitonin receptor agonist KBP‐336 and semaglutide results in durable weight loss. Eur J Pharmacol. 2023;954:175837. doi:10.1016/j.ejphar.2023.175837
Henriksen K, Broekhuizen K, de Boon WMI, et al. Safety, tolerability and pharmacokinetic characterisation of DACRA KBP‐042 in healthy male subjects. Br J Clin Pharmacol. 2021;87(12):4786‐4796. doi:10.1111/bcp.14921
KeyBioscience AG. Clinical trial results: a double‐blind, placebo‐controlled, randomized study to evaluate the efficacy and safety of KBP‐042 in patients with type 2 diabetes. EU Clinical Trials Register. 2019; Accessed December 7, 2023. https://www.clinicaltrialsregister.eu/ctr‐search/trial/2017‐001061‐24/results
KeyBioscience AG. A Clinical Study to Evaluate the Safety, Tolerability, PK, PD, and Efficacy of KBP‐089 in Patients With T2DM. 2020 Accessed December 7, 2023. clinicaltrials.gov. https://clinicaltrials.gov/study/NCT03907202
John LM, Kruse T, Raun K. Preclinical weight loss efficacy of AM833 in combination with Semaglutide in rodent models of obesity. J Endocr Soc. 2021;5(Supplement_1):A54. doi:10.1210/jendso/bvab048.108
Lau DCW, Erichsen L, Francisco AM, et al. Once‐weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double‐blind, placebo‐controlled and active‐controlled, dose‐finding phase 2 trial. The Lancet. 2021;398(10317):2160‐2172. doi:10.1016/S0140-6736(21)01751-7
Frias JP, Deenadayalan S, Erichsen L, et al. Efficacy and safety of co‐administered once‐weekly cagrilintide 2·4 mg with once‐weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double‐blind, active‐controlled, phase 2 trial. The Lancet. 2023;402(10403):720‐730. doi:10.1016/S0140-6736(23)01163-7
Novo Nordisk A/S. A Research Study to See How Well CagriSema Helps People With Excess Body Weight Lose Weight (REDEFINE 1). 2023 Accessed December 7, 2023. clinicaltrials.gov. https://clinicaltrials.gov/study/NCT05567796
Novo Nordisk A/S. A Research Study to See How Well CagriSema Helps People With Type 2 Diabetes and Excess Body Weight Lose Weight (REDEFINE 2). 2023 Accessed December 7, 2023. clinicaltrials.gov. https://clinicaltrials.gov/study/NCT05394519
Novo Nordisk A/S. A Research Study to See How Well CagriSema Helps People in China With Excess Body Weight Lose Weight (REDEFINE 6). 2023 Accessed December 7, 2023. clinicaltrials.gov. https://clinicaltrials.gov/study/NCT05996848
Novo Nordisk A/S. A Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor (REIMAGINE 2). 2023 Accessed December 7, 2023. clinicaltrials.gov. https://classic.clinicaltrials.gov/ct2/show/NCT06065540
Novo Nordisk A/S. A Research Study to See How Well CagriSema Compared to Tirzepatide Helps People With Obesity Lose Weight. 2023 Accessed December 7, 2023. clinicaltrials.gov. https://clinicaltrials.gov/study/NCT06131437
Eli Lilly and Company. FDA Approves Lilly's Zepbound™ (tirzepatide) for Chronic Weight Management, a Powerful New Option for the Treatment of Obesity or Overweight with Weight‐Related Medical Problems. 2023 Accessed December 7, 2023. https://investor.lilly.com/news‐releases/news‐release‐details/fda‐approves‐lillys‐zepboundtm‐tirzepatide‐chronic‐weight